Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Anna J. Slezak"'
Autor:
Abigail L. Lauterbach, Rachel P. Wallace, Aaron T. Alpar, Kirsten C. Refvik, Joseph W. Reda, Ako Ishihara, Taryn N. Beckman, Anna J. Slezak, Yukari Mizukami, Aslan Mansurov, Suzana Gomes, Jun Ishihara, Jeffrey A. Hubbell
Publikováno v:
npj Regenerative Medicine, Vol 8, Iss 1, Pp 1-13 (2023)
Abstract Non-healing wounds have a negative impact on quality of life and account for many cases of amputation and even early death among patients. Diabetic patients are the predominate population affected by these non-healing wounds. Despite the sig
Externí odkaz:
https://doaj.org/article/601c46ab07994fd8abb735c9a63a3160
Autor:
Abigail L. Lauterbach, Rachel P. Wallace, Aaron T. Alpar, Kirsten C. Refvik, Joseph W. Reda, Ako Ishihara, Taryn N. Beckman, Anna J. Slezak, Yukari Mizukami, Aslan Mansurov, Suzana Gomes, Jun Ishihara, Jeffrey A. Hubbell
Publikováno v:
npj Regenerative Medicine, Vol 8, Iss 1, Pp 1-1 (2023)
Externí odkaz:
https://doaj.org/article/0ef528f3aa074bfe9c42f09a1a03979d
Autor:
Rachel P. Wallace, Kirsten C. Refvik, Jennifer T. Antane, Kym Brünggel, Andrew C. Tremain, Michal R. Raczy, Aaron T. Alpar, Mindy Nguyen, Ani Solanki, Anna J. Slezak, Elyse A. Watkins, Abigail L. Lauterbach, Shijie Cao, D. Scott Wilson, Jeffrey A. Hubbell
Publikováno v:
bioRxiv
SummaryImmunogenic biologics trigger an anti-drug antibody (ADA) response in patients, which reduces efficacy and increases adverse reactions. Our laboratory has previously shown that targeting protein antigen to the liver microenvironment can reduce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::027b3e25897b526905b8338f110d6e48
https://europepmc.org/articles/PMC10104138/
https://europepmc.org/articles/PMC10104138/
Autor:
Shijie Cao, Chitavi D. Maulloo, Michal M. Raczy, Matthew Sabados, Anna J. Slezak, Mindy Nguyen, Ani Solanki, Rachel P. Wallace, Ha-Na Shim, D. Scott Wilson, Jeffrey A. Hubbell
SummaryThe only FDA-approved oral immunotherapy for a food allergy provides protection against accidental exposure to peanuts. However, this therapy often causes discomfort or side effects and requires long-term commitment. Better preventive and ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::353181093a4aa70ca3e902f3ae4e3d91
https://doi.org/10.1101/2023.03.23.534004
https://doi.org/10.1101/2023.03.23.534004
Autor:
Anna J. Slezak, Aslan Mansurov, Michal M. Raczy, Kevin Chang, Aaron T. Alpar, Abigail L. Lauterbach, Rachel P. Wallace, Rachel K. Weathered, Jorge E.G. Medellin, Claudia Battistella, Laura T. Gray, Tiffany M. Marchell, Suzana Gomes, Melody A. Swartz, Jeffrey A. Hubbell
Publikováno v:
ACS central science. 8(10)
Immune stimulating agents like Toll-like receptor 7 (TLR7) agonists induce potent antitumor immunity but are limited in their therapeutic window due to off-target immune activation. Here, we developed a polymeric delivery platform that binds excess u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4dc214c6bc220282e5352a4f2e159aad
https://pubmed.ncbi.nlm.nih.gov/36313164
https://pubmed.ncbi.nlm.nih.gov/36313164
Autor:
Aslan, Mansurov, Peyman, Hosseinchi, Kevin, Chang, Abigail L, Lauterbach, Laura T, Gray, Aaron T, Alpar, Erica, Budina, Anna J, Slezak, Seounghun, Kang, Shijie, Cao, Ani, Solanki, Suzana, Gomes, John-Michael, Williford, Melody A, Swartz, Juan L, Mendoza, Jun, Ishihara, Jeffrey A, Hubbell
Publikováno v:
Nature biomedical engineering. 6(7)
Immune-checkpoint inhibitors have shown modest efficacy against immunologically 'cold' tumours. Interleukin-12 (IL-12)-a cytokine that promotes the recruitment of immune cells into tumours as well as immune cell activation, also in cold tumours-can c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b3841d645e70c071747ec7465ab50a32
https://pubmed.ncbi.nlm.nih.gov/35534574
https://pubmed.ncbi.nlm.nih.gov/35534574